Philip Morris International IncNYSE: PM
Consumer Staples · Tobacco
$179.03
-0.23%
Vol: 3.8M
Research Digest
Thursday, June 18, 2026
Philip Morris declares $1.47 quarterly dividend and faces €7M Italian fine for misleading smoke-free product marketing.
Philip Morris International declared a quarterly dividend of $1.47 per share on June 11, 2026, payable July 20, 2026. At the June 2 dbAccess Global Consumer Conference, CEO Jacek Olczak updated 2026 full-year reported diluted EPS guidance to $7.18–$7.33, reflecting a ~$500M non-cash impairment of deconsolidated Canadian affiliate RBH, while maintaining underlying adjusted EPS growth of 10.2%–12.2%. Italy's competition authority fined PMI's Italian unit €7M for allegedly misleading marketing of non-combustion products. The smoke-free business, led by IQOS with 43M+ users, accounted for 43% of Q1 2026 net revenues. Morgan Stanley raised its price target to $200 from $190, maintaining Overweight.
Previous Market Intelligence
13 daysJun 17No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours. The latest dated item, a $1.47 quarterly dividend declaration, is from June 10, outside the window.
Jun 14Philip Morris International declares a regular quarterly dividend of $1.47 per share.Mixed▶
On June 10, Philip Morris International's board declared a regular quarterly dividend of $1.47 per common share, payable July 20, 2026, underscoring its commitment to shareholder returns. The announcement follows recent guidance changes: the company cut its 2026 reported diluted EPS outlook to $7.18-$7.33, citing currency pressures and an expected $500 million non-cash impairment tied to Canadian affiliate Rothmans, Benson & Hedges. PMI continues to lean on smoke-free products such as IQOS and ZYN, now over 40% of revenue, as its core growth driver, including an expanded ZYN partnership with Ducati Corse. Shares trade near $174. The key risk is currency and impairment-related earnings drag offsetting smoke-free momentum.
May 21Philip Morris announces Massimo Andolina as new Group CFO effective Aug 1, 2026 (May 18-20); stock near 52-week high of $191.57 on FDA tailwind and IQOS growth.Positive▶
Philip Morris International announced on May 18-20 that Massimo Andolina (current President Europe Region) will become Group CFO effective August 1, 2026, succeeding Emmanuel Babeau (who advises CEO Jacek Olczak through March 2027). Andolina has nearly two decades at PMI. The stock traded at $191.57 on May 19, near the 52-week high of $193.05. Earlier in May, shares surged 6%+ on favorable FDA guidance reducing regulatory uncertainty (FDA will not prioritize enforcement against products with pending PMTA applications). Q1 revenue grew 9.1% YoY, exceeding consensus and prompting raised FY guidance. IQOS surpassed Marlboro to become PMI's #1 nicotine brand by volume in head-to-head markets. Smoke-free products = 43% of Q1 net revenues.
May 20Philip Morris jumps ~5.6% after FDA signals softer enforcement on pending PMTA nicotine products, reinforcing IQOS-led smoke-free thesis.Positive▶
Philip Morris International shares rallied roughly 5.6% after the FDA issued new guidance indicating it will deprioritize enforcement against products with pending, accepted premarket tobacco product applications (PMTAs), materially reducing regulatory overhang for PMI and peers navigating the approval queue. The move compounds momentum from Q1 2026 earnings, where smoke-free products including IQOS hit 43% of total net revenue and the company beat expectations. Shares are up ~20% over the past month and ~19.7% YTD. PMI is reaffirming its growth outlook, leaning on smoke-free penetration (>40% of revenue) as its long-term growth driver. Risk: after the run-up, the stock now trades close to its average analyst price target, with valuation tools flagging it as full to slightly overvalued.
May 19Philip Morris stock nears $200 as favorable FDA guidance and IQOS overtakes MarlboroPositive▶
Philip Morris shares traded at $191.50 on May 18, up over 6% recently after favorable FDA guidance reduced regulatory uncertainty for nicotine products by deprioritizing enforcement against products with pending PMTAs. IQOS surpassed Marlboro to become PMI's number-one nicotine brand by volume in markets where both products compete directly. Q1 2026 revenue rose 9.1% YoY, beating expectations and prompting management to raise full-year earnings guidance, with smoke-free products generating 43% of net revenues. PMI held its virtual annual meeting on May 6, reelecting all directors and rejecting a shareholder proposal on filter cleanup costs. The company also expanded its ZYN partnership with Ducati Corse MotoGP for 2026 and beyond. Risk: ongoing regulatory and ESG scrutiny on nicotine pouches and combustibles.
May 18Philip Morris stock approaches $200 as FDA enforcement-discretion guidance reduces regulatory risk on nicotine pouches/e-vapor and IQOS surpasses Marlboro by volume.Positive▶
Philip Morris International shares surged over 6% earlier in May after the FDA said it would not prioritize enforcement against products with pending premarket tobacco applications, materially reducing regulatory overhang on the next-generation nicotine portfolio. The stock closed above $180, within striking distance of its February record near $191. Q1 revenue rose 9.1% YoY, beating consensus, and management raised full-year EPS guidance. IQOS overtook Marlboro as PM's top nicotine brand by volume in direct-competition markets, and smoke-free products now account for ~43% of net revenues. Shareholders rejected a proposal on filter cleanup costs at the May 6 annual meeting. Stock is up ~20% YTD. Risk: any reversal in FDA posture or weaker IQOS uptake in newer markets could unwind the rerating.
May 15Philip Morris surges 6.5% to $182 after FDA enforcement relief and IQOS surpasses Marlboro in shared marketsPositive▶
Philip Morris International shares jumped 6.5% on May 11 to $182.11 after the FDA announced it would not prioritize enforcement against products with pending and accepted premarket tobacco product applications, significantly reducing regulatory risk. IQOS surpassed Marlboro to become PMI's number-one nicotine brand by volume in markets where both compete, and smoke-free products now account for 43% of Q1 net revenues. Q1 revenue rose 9.1% YoY exceeding expectations, prompting management to raise full-year EPS guidance. At the May 6 virtual annual meeting, the company highlighted FY2025 revenue above $40B, nearly $17B from smoke-free products, and five years of smoke-free volume growth. Risk: on May 12 the European Parliament called for an urgent EU investigation into undisclosed PMI meetings with EU trade officials over alleged regulatory influence.
May 14Philip Morris International surged 9.3% on May 12 to $186.93 after favorable FDA guidance reduced enforcement risk for products with pending PMTAs, with IQOS continuing to take share from Marlboro.Positive▶
On May 12, 2026, Philip Morris International shares jumped 9.3% to $186.93 after a 6.5% surge to $182.11 on May 11, driven by FDA guidance that it would not prioritize enforcement against nicotine products with pending and accepted premarket tobacco product applications (PMTAs). Markets read the policy as a meaningful reduction in regulatory risk across PM's smoke-free portfolio, particularly ZYN and IQOS. The rally extends momentum from Q1 revenue +9.1% YoY and a raised full-year EPS guide, with IQOS becoming PM's #1 nicotine brand by volume in markets where both IQOS and Marlboro compete. Smoke-free products now generate 43% of total net revenues. Why it matters: the FDA policy effectively grants a legal-safe-harbor for products awaiting approval. Risk: GF Value flags 29.1% overvaluation versus a $141 fair value, suggesting a near-term valuation pull-back is plausible.
May 13Philip Morris surges 9.3% to $186.93 on May 12 after favorable FDA guidance reduces nicotine product regulatory risk; IQOS now #1 brand.Positive▶
Philip Morris International shares rose 9.3% to $186.93 on May 12 following favorable FDA guidance announcing it would not prioritize enforcement against products with pending and accepted premarket tobacco product applications. The markets interpreted this as a significant reduction in regulatory risk for the company s smoke-free portfolio. Q1 2026 revenue rose 9.1% YoY, exceeding Wall Street expectations and prompting management to raise full-year earnings guidance. IQOS has surpassed Marlboro to become PM s #1 nicotine brand by volume in markets where they compete directly. Smoke-free products now account for ~43% of total net revenues. The stock has gained 16.5% over the past month. GF Value indicates PM is trading 32.5% above estimated fair value of $141.04.
May 12Philip Morris jumped ~5.6% after the FDA signaled it would not prioritize enforcement on nicotine products with pending PMTAs; smoke-free products now 43% of Q1 revenue.Positive▶
Philip Morris shares rallied roughly 5.6% intraday after the FDA issued new guidance indicating it will not prioritize enforcement against nicotine products with pending and accepted premarket tobacco product applications (PMTAs), a favorable regulatory shift for IQOS and ZYN-style products. PMI held its virtual Annual Meeting of Shareholders on May 6 with ~81% of shares represented; all 10 directors and PwC SA were reelected/ratified, and a shareholder proposal on filter cleanup costs was rejected. Management highlighted 2025 net revenues above $40B (nearly $17B from smoke-free) and called out five consecutive years of smoke-free volume growth. Smoke-free generated 43% of Q1 2026 net revenue. Stock recently traded around $173.08, up ~12.5% YTD, near a 52-week high of $189.80.
May 11Philip Morris holds 2026 virtual annual meeting; smoke-free products generate 43% of Q1 net revenues, fifth consecutive year of volume growthPositive▶
Philip Morris International held its 2026 virtual Annual Meeting of Shareholders on May 6, 2026. Chairman Andre Calantzopoulos and CEO Jacek Olczak highlighted 2025 net revenues above $40B with nearly $17B from smoke-free products, plus five consecutive years of smoke-free volume growth. Smoke-free products generated 43% of Q1 2026 net revenues across 105+ markets with an estimated 43M legal-age users. Shareholders elected ten directors, approved executive pay on an advisory basis, and ratified PwC as auditors with ~81% turnout. Shares closed near $171.01 on May 8 after a six-day rally.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| PMPHILIP | $179.03 | -0.23% | -5.4% | 19.5x | 0.41 | $278.0B |
| MOALTRIA | $69.21 | +0.38% | -5.7% | 11.8x | 0.50 | $115.4B |
| WMTWALMART | $117.25 | -0.75% | -10.4% | 35.6x | 0.60 | $932.5B |
| COSTCOSTCO | $952.10 | -1.40% | -11.4% | 42.0x | 0.87 | $421.9B |
| PGPROCTER | $151.06 | +0.33% | +5.6% | 21.2x | 0.39 | $350.2B |
| KOCOCA | $79.50 | -0.54% | -2.6% | 22.8x | 0.35 | $341.6B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.